Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Genitourinary 2Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 26Lung Neoplasms 23Neoplasms 7Small Cell Lung Carcinoma 5Neoplasm Metastasis 4Mesothelioma 4Breast Neoplasms 4Vomiting 3Nausea 3Triple Negative Breast Neoplasms 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Kidney Neoplasms 2Head and Neck Neoplasms 2Brain Neoplasms 2Stomach Neoplasms 1Radiation Pneumonitis 1Postoperative Complications 1Pain, Postoperative 1Nasopharyngeal Neoplasms 1Multiple Myeloma 1Mesothelioma, Malignant 1Melanoma 1Malnutrition 1Lymphoma 1Lung Diseases, Interstitial 1Liver Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1

Interventions

pembrolizumab 44Carboplatin 17Pemetrexed 14Paclitaxel 13Cisplatin 13lenvatinib 5Etoposide 5Docetaxel 5epacadostat 4Gemcitabine 4Albumin-Bound Paclitaxel 4durvalumab 3Nivolumab 3130-nm albumin-bound paclitaxel 3spartalizumab 2olaparib 2Saline Solution 2Immune Checkpoint Inhibitors 2Dexamethasone 2Acetaminophen 2sacituzumab govitecan 1ribociclib 1patritumab deruxtecan 1osimertinib 1etoposide phosphate 1efineptakin alfa 1cemiplimab 1camrelizumab 1avelumab 1atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body × Dexamethasone × Thoracic × Clear all
NCT06788912 2026-05-26

MK-3475-01E

Merck Sharp & Dohme LLC

Phase 2 Recruiting
60 enrolled
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lung Neoplasms

NCT03950674 2024-06-10

MK-3475-189

Merck Sharp & Dohme LLC

Phase 3 Completed
40 enrolled 20 charts
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡